Year: 2025
Type: dissertation
Abstract: The retina, a complex neural tissue, converts light into electrical signals through phototransduction, making it a valuable model for studying neural mechanisms, drug effects, and retinal diseases. Its high sensitivity to physical and chemical disturbances allows photoreceptor signaling to serve as an effective tool for biocompatibility testing of potential drug molecules and nanostructures. Transretinal electroretinography (tERG), an ex vivo technique for recording extracellular field potentials across isolated retinae, provides a controlled platform for evaluating photoreceptor and bipolar cell functions. This method enables rapid assessment of drug effects by analyzing changes in response amplitude, kinetics, and light sensitivity. In the initial studies of this thesis, tERG was employed to evaluate and quantify the inhibition constants of CB-5083, a valosin-containing protein (VCP) inhibitor, and avanafil, a phosphodiesterase-5 (PDE5) inhibitor, on light-activated PDE6 in murine retinae. PDE6 is a critical enzyme in the G-protein signaling cascade in phototransduction, regulating cyclic GMP levels and controlling photoreceptor activity. G-protein-coupled pathways are significant targets for pharmacological intervention. CB-5083 clinical trials for cancer treatment were halted because of adverse visual effects, including photophobia and dyschromatopsia, which were believed to stem from the inhibition of PDE6. Our tERG analysis confirmed this hypothesis, revealing that CB-5083 inhibits PDE6 with an inhibition constant of 80 nM. Avanafil was also found to cause dose-dependent PDE6 inhibition, primarily affecting rod and cone photoreceptors by slowing their response kinetics. The inhibition constants for light-activated PDE6 were determined as 1.74 μM in rods and 6.3 μM in cones, indicating a weaker inhibitory effect compared to other PDE5 inhibitors such as sildenafil and zaprinast. No significant impact was observed on rod bipolar cell signaling, suggesting that avanafil's effects were primarily confined to photoreceptor function. The second phase of this research contained development of a closed-circulation tERG system for murine retinae to facilitate testing with minimal amounts of drug molecules or nanostructures. This system maintained retinal viability and functionality during extended experiments, with rod responses remaining stable for at least 42 hours and rod and cone bipolar cell responses lasting at least 12 hour closed-perfusion period. The setup was validated using IBMX, a non-specific PDE inhibitor, and demonstrated its utility in biocompatibility testing with zwitterionic polymers such as poly(sulfobetaine methacrylate) (PSMBA) and its monomer SBMA, both of which showed no adverse effects on rod and bipolar cell responses. This method proved effective for long-term assessments using small volumes of perfusate, providing a scalable and cost-efficient platform for preclinical studies. In the final stage, the small-volume closed-circulation tERG system was adapted for postmortem human retinal tissue. Donor eyecups, which had enucleation delays of one to four hours, successfully maintained steady rod photoreceptor responses throughout a 12-hour perfusion period. This method bridges preclinical research and clinical applications, reducing reliance on animal models and enhancing translational relevance. As a summary, this work establishes tERG as a powerful tool for preclinical research, offering detailed insights into drug-induced retinal effects and supporting the development of effective therapeutic strategies.
Source: Aaltodoc (Aalto University)
Author: Saeid, Sama
Institution: Aalto University
Language: English
Subfield: Ophthalmology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funder: Aalto-Yliopisto
OpenAlex ID: W6997125496
